Literature DB >> 17030707

Relative risk of progressive glaucomatous visual field loss in patients enrolled and not enrolled in a prospective longitudinal study.

David B Henson1, Siddesh Shambhu.   

Abstract

OBJECTIVE: To establish the relative risk of progressive visual field loss in a sample of glaucomatous eyes enrolled in a prospective longitudinal study vs a matched sample of eyes not enrolled in a study.
METHODS: The first visual field records of 66 glaucomatous eyes enrolled in a prospective longitudinal study (mean follow-up time, 3.4 years; mean number of visual field tests, 8.3) were matched to 66 eyes from patients not enrolled in a study (mean follow-up time, 3 years; mean number of visual field tests, 3.7). Eyes were matched on the basis of (1) time of enrollment, (2) length of follow-up, and (3) the extent and spatial pattern of visual field loss. Linear regression of global visual field indexes was used to measure change and the relative risk of progression was calculated for a series of progression criteria sample.
RESULTS: The relative risk of progressive visual field loss was on average 368% (range, 209%-673%) higher in the eyes not enrolled in a prospective longitudinal study.
CONCLUSION: Selection bias may reduce the risk of progressive visual field loss in patients enrolled in longitudinal studies.

Entities:  

Mesh:

Year:  2006        PMID: 17030707     DOI: 10.1001/archopht.124.10.1405

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  3 in total

1.  Prior rates of visual field loss and lifetime risk of blindness in glaucomatous patients undergoing trabeculectomy.

Authors:  W S Foulsham; L Fu; A J Tatham
Journal:  Eye (Lond)       Date:  2015-08-28       Impact factor: 3.775

2.  Why Do People (Still) Go Blind from Glaucoma?

Authors:  Remo Susanna; Carlos Gustavo De Moraes; George A Cioffi; Robert Ritch
Journal:  Transl Vis Sci Technol       Date:  2015-03-09       Impact factor: 3.283

3.  Ten-year outcomes in newly diagnosed glaucoma patients: mortality and visual function.

Authors:  Tarun Sharma; John F Salmon
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.